Prograf-XL + Prograf + MMF
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Liver Transplantation
Conditions
Liver Transplantation, Transplantation Immunology, Host vs Graft Reaction
Trial Timeline
Dec 1, 2007 → Sep 1, 2009
NCT ID
NCT00720408About Prograf-XL + Prograf + MMF
Prograf-XL + Prograf + MMF is a phase 3 stage product being developed by Astellas Pharma for Liver Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00720408. Target conditions include Liver Transplantation, Transplantation Immunology, Host vs Graft Reaction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00717678 | Phase 3 | Completed |
| NCT00720408 | Phase 3 | Completed |
Competing Products
20 competing products in Liver Transplantation